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3.0 44.8 3.0 41.1 6.5† 43.9 6.2‡
4.3 5.2 5.2 2.3 2.7† 3.6 3.5‡
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henomenon or Syndrome Y
Microvascular Angina
waiting Recognition
r. Cannon is to be complimented on his important contributions
n the description of the elusive pathophysiology of microvascular
ngina. We would like to contribute to his otherwise excellent
eview (1) recently published in the Journal by making mention of
nother condition that also depends on an impairment in the
egulation of coronary microvascular resistances and that, there-romes. This condition, known as the coronary slow-flow phe-
omenon (CSFP), is increasingly recognized as a separate clinical
ntity along with the “classic” coronary syndrome X based on 3
egrees of evidence: 1) the coronary syndrome X and the CSFP
iffer mechanistically; 2) the CSFP has typical clinical features that
iffer strikingly from those of coronary syndrome X; and, finally, 3)
ts prognosis is not as benign as that traditionally described for
oronary syndrome X.
Although a number of formal definitions have been proposed,
he CSFP essentially consists of a delay in the progression of the
ontrast injected in the coronary vasculature during coronary
ngiography. Importantly, invasive studies have demonstrated that,
ompatible with the delayed opacification, resting coronary artery
esistances are abnormally elevated in these patients; in strikingnctioand N
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July 13, 2010:238–42esistances respond normally to vasodilator stimuli such as papav-
rine and adenosine and during exercise (2,3). As such, abnormal-
ties in the regulation of microvascular tone occur only in resting
onditions in patients with the CSFP, and while coronary syn-
rome X is characterized by an impaired coronary flow reserve, the
SFP is associated with a normal, or even supranormal, one (3). In
ine with this abnormality, while coronary syndrome X patients
ypically experience angina under stress, the CSFP is more
ommonly associated with rest angina. Further, while there is
eneral agreement that coronary syndrome X occurs more com-
only in post-menopausal women, the CSFP has been typically
ound in young male smokers (4). Finally, and most importantly,
ife-threatening arrhythmias and sudden cardiac death have been
escribed in these patients (5).
A number of issues still need to be clarified with regard to the
athogenesis, clinical presentation, therapy, and outcome of the
SFP. Despite these unsolved issues, the CSFP (or coronary
yndrome Y, given the proposed role of neuropeptide Y [2]) should
e finally recognized the status of separate clinical entity within the
ramework of microvascular angina, and computation of the
hrombolysis In Myocardial Infarction frame count should be-
ome a routine procedure. Further, microvascular angina should
ot be considered a single condition with a homogeneous patho-
hysiology and clinical pattern. Recognizing this complexity will
robably help to explain many of the controversies well described
y Dr. Cannon.
assimo Fineschi, MD
Tommaso Gori, MD, PhD
Department of Cardiology
niversity Medical Center
angenbeckstr. 1
5131 Mainz
ermany
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eply
rs. Fineschi and Gori propose a new syndrome of coronary
icrovascular dysfunction, manifest by slow passage of contrast
edia in coronary arteries of patients presenting with acute
hest pain. They suggest “coronary syndrome Y” to distinguish
his syndrome from “syndrome X” used by some investigatorsnd clinicians to identify the larger group of patients with
ngina-like chest pain (rest or effort provoked), ischemic-
ppearing electrocardiographic response to exercise stress, and
ormal coronary angiograms.
Consistent with my discussion in the Journal (1), I believe that
yndrome Y with the “coronary slow-flow phenomenon” has
ncertainties similar to other groups of patients with chest pain
espite normal coronary angiograms, whether designated as syn-
rome X, microvascular angina, or something else. Thus, is this
yndrome a primary abnormality of coronary microvascular func-
ion or a result of activated platelets and vasoactive debris from
laques in epicardial arteries not apparent on visual assessment of
oronary angiograms? From a clinical perspective, what criteria are
ecessary for diagnosis? Assessment of the flow of contrast media
rom epicardial arteries into the myocardium is largely subjective
nd may be confounded by dilation of epicardial arteries due to
dministration of nitrates before coronary angiography, thus re-
ucing flow velocity at that level of the circulation. Accordingly,
hat Thrombolysis In Myocardial Infarction frame count could
dentify patients with this syndrome with acceptable sensitivity and
pecificity? Are there characteristic electrocardiographic changes to
uggest ischemia? Are troponin levels elevated to suggest myone-
rosis? Are wall motion abnormalities present on echocardiogra-
hy? In this regard, intense microvascular constriction, possibly
ue to neurohormonal activation accompanying psychological or
ther life stress, has been proposed to account for the Takotsubo
yndrome of reversible apical ballooning (recently reviewed by
kashi et al. [2]), but such striking wall motion abnormalities
o not appear with any regularity in reports referenced by
rs. Fineschi and Gori. Can imaging studies such as cardiac
agnetic resonance imaging show evidence of endocardial hypo-
erfusion if performed proximate to an episode of chest pain for
atients with recurrent symptoms? Finally, what treatments cur-
ently available to clinicians are effective in managing symptoms
nd preventing pathophysiologic (once defined) features of this
ew syndrome?
I look forward to additional clinical research that may well
egitimize this, and other, syndromes of chest pain with normal
oronary arteries and structurally normal hearts.
Richard O. Cannon III, MD
National Heart, Lung, and Blood Institute
ational Institutes of Health
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